Bo and I discuss some of the leading candidates for extending both human lifespan and “health-span”, including metformin, nicotinamide riboside & nicotinamide mononucleotide, and caloric restriction. We also chat about some of the companies working in this area, as well as novel business models that may or may not be a strategy to enable rigorous research of something as difficult to study as human lifespan.
All content for Wired to be Weird is the property of Ian McLaughlin & Bo Allen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Bo and I discuss some of the leading candidates for extending both human lifespan and “health-span”, including metformin, nicotinamide riboside & nicotinamide mononucleotide, and caloric restriction. We also chat about some of the companies working in this area, as well as novel business models that may or may not be a strategy to enable rigorous research of something as difficult to study as human lifespan.
In part 2 of our discussion of Neuralink, Elon Musk's newly announced company, we focus more on what it might be like if this kind of a technology were realized, as well as how likely it might be.
Wired to be Weird
Bo and I discuss some of the leading candidates for extending both human lifespan and “health-span”, including metformin, nicotinamide riboside & nicotinamide mononucleotide, and caloric restriction. We also chat about some of the companies working in this area, as well as novel business models that may or may not be a strategy to enable rigorous research of something as difficult to study as human lifespan.
